Abiopharma

New Form 6-K - ALTERITY THERAPEUTICS LTD Filed: 2025-09-08 AccNo: 0001213900-25-085289 Size: 33 KB

NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults

BullFrog AI’s bfPREP™ and bfLEAP®Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

New Form 8-K - Summit Therapeutics Inc. Filed: 2025-09-08 AccNo: 0001599298-25-000137 Size: 5 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Aprea Therapeutics, Inc. Filed: 2025-09-08 AccNo: 0001558370-25-011909 Size: 4 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Curaleaf Joins S&P/TSX Composite Index

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

New Form 6-K - ONCOLYTICS BIOTECH INC Filed: 2025-09-08 AccNo: 0001129928-25-000074 Size: 36 KB

Cybin - Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

New Form 6-K - GSK plc Filed: 2025-09-08 AccNo: 0001654954-25-010455 Size: 6 MB